Trial Profile
An Investigator Initiated, Open Label, Randomized, Controlled, Multicentric Study, to assess the Safety and Efficacy of Nimotuzumab (BIOMAb-EGFR) concurrent with Cisplatin and Radiotherapy in histologically Documented Squamous Cell Carcinoma of the Cervix.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2017
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin
- Indications Cervical cancer
- Focus Therapeutic Use
- 12 Sep 2017 Status changed from recruiting to active, no longer recruiting as per the results presented at the 42nd European Society for Medical Oncology Congress
- 12 Sep 2017 Results (n=74) assessing safety and efficacy at the end of 2 year presented at the 42nd European Society for Medical Oncology Congress
- 08 Feb 2010 New trial record